Clinical TrialApr 29, 2026, 04:08 PM
ALEC Discontinues Phase 2 Alzheimer's Trial for Nivisnebart
AI Summary
Alector, Inc. announced the discontinuation of its Phase 2 PROGRESS-AD trial for nivisnebart (AL101/GSK4527226) in individuals with early Alzheimer's disease. An independent data monitoring committee (IDMC) concluded that the trial was unlikely to meet its primary endpoint of slowing disease progression. Despite this setback, Alector remains focused on advancing its broader pipeline of novel ABC-enabled candidates, including an anti-Aβ antibody for AD targeting an IND submission in Q1 2027 and a GCase ERT for PD targeting an IND in 2027.
Key Highlights
- Phase 2 PROGRESS-AD trial for nivisnebart (AL101/GSK4527226) in early Alzheimer's disease discontinued.
- Independent data monitoring committee (IDMC) determined the trial unlikely to meet its primary endpoint.
- Alector continues AL037/AL137 (anti-Aβ antibody) towards Q1 2027 IND submission.
- AL050 (GCase ERT for Parkinson's disease) targets IND application in 2027.
- Advancing ABC-enabled siRNA programs including AL064/AL164 (tau), ADP062-ABC (alpha synuclein), and ADP065-ABC (NLRP3).
Price Impact
More from ALEC